Literature DB >> 19281227

Dissecting molecular mechanisms in the living brain of dementia patients.

Jorge R Barrio1, Nagichettiar Satyamurthy, Sung-Cheng Huang, Andrej Petric, Gary W Small, Vladimir Kepe.   

Abstract

Understanding the molecular mechanisms associated with the development of dementia is essential for designing successful interventions. Dementia, like cancer and cardiovascular disease, requires early detection to potentially arrest or prevent further disease progression. By the time a neurologist begins to manage clinical symptoms, the disease has often damaged the brain significantly. Because successful treatment is the logical goal, detecting the disease when brain damage is still limited is of the essence. The role of chemistry in this discovery process is critical. With the advent of molecular imaging, the understanding of molecular mechanisms in human neurodegenerative diseases has exploded. Traditionally, knowledge of enzyme and neurotransmitter function in humans has been extrapolated from animal studies, but now we can acquire data directly from both healthy and diseased human subjects. In this Account, we describe the use of molecular imaging probes to elucidate the biochemical and cellular bases of dementia (e.g., Alzheimer's disease) and the application of these discoveries to the design of successful therapeutic interventions. Molecular imaging permits observation and evaluation of the basic molecular mechanisms of disease progression in the living brains of patients. 2-Deoxy-2-[(18)F]fluoro-d-glucose is used to assess the effect of Alzheimer's disease progression on neuronal circuits projecting from and to the temporal lobe (one of the earliest metabolic signs of the disease). Recently, we have developed imaging probes for detection of amyloid neuropathology (both tau and beta-amyloid peptide deposits) and neuronal losses. These probes allow us to visualize the development of pathology in the living brain of dementia patients and its consequences, such as losses of critical neurons associated with memory deficits and other neuropsychiatric impairments. Because inflammatory processes are tightly connected to the brain degenerative processes, inflammation is now emerging as an important target for new molecular imaging probes. The combination of molecular probes targeting various processes of dementia is a useful tool for detailed monitoring of disease mechanism, progression, and diagnosis, as well as for the development of rational strategies for promising therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19281227     DOI: 10.1021/ar800189x

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  10 in total

1.  QSAR studies for prediction of cross-β sheet aggregate binding affinity and selectivity.

Authors:  Katryna Cisek; Jeff Kuret
Journal:  Bioorg Med Chem       Date:  2012-01-12       Impact factor: 3.641

2.  18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.

Authors:  Hank F Kung; Seok Rye Choi; Wenchao Qu; Wei Zhang; Daniel Skovronsky
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

3.  In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging.

Authors:  Jorge R Barrio; Gary W Small; Koon-Pong Wong; Sung-Cheng Huang; Jie Liu; David A Merrill; Christopher C Giza; Robert P Fitzsimmons; Bennet Omalu; Julian Bailes; Vladimir Kepe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

4.  Synthesis and In Vitro Evaluation of Imidazo[1,2-b]pyridazines as Ligands for β-Amyloid Plaques.

Authors:  Fanxing Zeng; David Alagille; Gilles D Tamagnan; Brian J Ciliax; Allan I Levey; Mark M Goodman
Journal:  ACS Med Chem Lett       Date:  2010-03-11       Impact factor: 4.345

5.  Comparative evaluation of Logan and relative-equilibrium graphical methods for parametric imaging of dynamic [18F]FDDNP PET determinations.

Authors:  Koon-Pong Wong; Vladimir Kepe; Magnus Dahlbom; Nagichettiar Satyamurthy; Gary W Small; Jorge R Barrio; Sung-Cheng Huang
Journal:  Neuroimage       Date:  2011-12-16       Impact factor: 6.556

Review 6.  Positron emission tomography radioligands for in vivo imaging of Aβ plaques.

Authors:  N Scott Mason; Chester A Mathis; William E Klunk
Journal:  J Labelled Comp Radiopharm       Date:  2013 Mar-Apr       Impact factor: 1.921

7.  Effective synthesis of chiral N-fluoroaryl aziridines through enantioselective aziridination of alkenes with fluoroaryl azides.

Authors:  Li-Mei Jin; Xue Xu; Hongjian Lu; Xin Cui; Lukasz Wojtas; X Peter Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2013-04-15       Impact factor: 15.336

8.  Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Authors:  Seok Rye Choi; Geoff Golding; Zhiping Zhuang; Wei Zhang; Nathaniel Lim; Franz Hefti; Tyler E Benedum; Michael R Kilbourn; Daniel Skovronsky; Hank F Kung
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

Review 9.  Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD.

Authors:  Mario F Mendez
Journal:  Arch Med Res       Date:  2012-11-21       Impact factor: 2.235

10.  PET imaging of neuropathology in tauopathies: progressive supranuclear palsy.

Authors:  Vladimir Kepe; Yvette Bordelon; Adam Boxer; Sung-Cheng Huang; Jie Liu; Frederick C Thiede; John C Mazziotta; Mario F Mendez; Natacha Donoghue; Gary W Small; Jorge R Barrio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.